Lobbying registrant · LD-2 disclosures
Regeneron Pharmaceuticals, Inc
New York
40 filings · 1 client · 6 lobbyists registered · 2016–2026 · latest filed Jul 21, 2026
Fees billed to clients
$0
never billed a fee — files for itself
Its own lobbying spend
$13.7M
filed on its own behalf
Clients represented
1
6 lobbyists registered
Note · At least one filing discloses a foreign entity with an interest in a client this registrant represents. Those disclosures are listed below.
Reported spend over time
Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Who they lobby for
This registrant files only on its own behalf — it has never reported a fee for representing anyone else.
Reported as lobbying expenses
Money reported as spent on lobbying rather than as a fee charged to a client.
What they lobby on
Issue areas declared on the filings, ranked by how many filings name each one.
Health Issues
HCR · 1 client
40 filings
$13.7M on those filings
Medicare/Medicaid
MMM · 1 client
39 filings
$13.6M on those filings
Copyright/Patent/Trademark
Who does the lobbying
Every lobbyist named on this registrant's filings.
- Maya Bermingham33 filings1 client · through 2024
- Katherine HaddadCovered position: Staff Asst., Legislative Coordinator, Legislative Asst., and Sr. Legislative Asst., to Rep. Fred Upton.28 filings1 client · through 2026
- Valerie Volpe23 filings1 client · through 2024
- Maddie DavidsonCovered position: Health Policy Director, Legislative Assistant, Sen. Mike Braun; Professional Staff Member, Staff Assistant, Senate Committee on Finance16 filings1 client · through 2026
- Eben Duross
Foreign interests disclosed
Every foreign entity named on this registrant's filings.
Sanofi S.A.
France
1 filing
through 2016
What this discloses · An LD-2 reports foreign entities that hold an interest in, or contribute to, the client — so these are foreign interests behind the organizations this registrant files for, not owners of the registrant itself. Disclosure is a reporting requirement, not an allegation.
The filings
The 20 most recent of 40 filings. Every figure above is built from these records.
This record groups every filed spelling of the registrant's name into one entity, so punctuation variants of the same firm read as one. The grouping is the registrant's normalized name — firms that file under genuinely different names appear separately. Handle: regeneron-pharmaceuticals-inc.